TheraRadar

Pharma Intelligence, Simplified

Emerging Biotechs

Companies with 1-10 approved drugs showing momentum: recent approvals, priority reviews, and active pipelines Updated: 3/5/2026

100
Emerging Biotechs
1-10 approved drugs
78
Phase 3 Trials
Near approval
90
With Priority Review
FDA fast-tracked
48
Avg Score
Momentum indicator

Scoring Methodology

Companies scored based on: Recent Approvals (3yr) × 20 + Priority Reviews × 10 + Phase 3 Trials × 5 + Phase 2 Trials × 2. Higher scores indicate momentum.

Company Approved Ph3 Ph2 Priority Score Top Drugs
Regeneron 2 recent 8 76 102 7 694
Vertex Pharmaceuticals 2 recent 7 0 0 7 110
ACCORD BIOPHARMA INC. 5 recent 5 0 0 0 100
INCYTE CORP 2 recent 5 0 0 5 90
IPSEN 2 recent 4 0 0 4 80
LEADIANT BIOSCI INC 7 0 0 7 70
GLAUKOS 2 recent 5 0 0 3 70
DAIICHI SANKYO INC 2 recent 4 0 0 3 70
AUCTA 3 recent 7 0 0 0 60
VANDA PHARMS INC 2 recent 6 0 0 2 60
NEUROCRINE 2 recent 3 0 0 2 60
SPRINGWORKS 2 recent 2 0 0 2 60
BTG INTL 1 recent 5 0 0 4 60
SHANGHAI HENLIUS BIOTECH 3 recent 3 0 0 0 60
ENTASIS THERAP 2 recent 2 0 0 2 60
XANODYNE PHARM 9 0 0 5 50
CUBIST PHARMS LLC 5 0 0 5 50
CMP DEV LLC 2 recent 7 0 0 1 50
OTSUKA 1 recent 10 0 0 3 50
AMICUS THERAP US 2 recent 3 0 0 1 50
SENTYNL THERAPS INC 1 recent 4 0 0 3 50
PURDUE PHARMA LP 1 recent 9 0 0 3 50
MIRUM 1 recent 3 0 0 3 50
CARWIN PHARM ASSOC 2 recent 2 0 0 1 50
INDIVIOR 1 recent 6 0 0 3 50
CHIESI FARMACEUTICI SPA 1 recent 3 0 0 3 50
IONIS PHARMS INC 2 recent 2 0 0 1 50
INTL MEDICATION SYS 1 recent 10 0 0 2 40
KINDOS 1 recent 6 0 0 2 40
ZENARA 2 recent 5 0 0 0 40
STERISCIENCE 2 recent 9 0 0 0 40
HAINAN POLY 1 recent 10 0 0 2 40
VALIDUS PHARMS 10 0 0 4 40
MILLA PHARMS 1 recent 9 0 0 2 40
ACTELION 1 recent 7 0 0 2 40
MSN PHARMACEUTICALS INC 2 recent 3 0 0 0 40
DECIPHERA PHARMS 1 recent 2 0 0 2 40
ROSEMONT PHARMS 2 recent 2 0 0 0 40
ACADIA PHARMS INC 1 recent 3 0 0 2 40
ALNYLAM PHARMS INC 4 0 0 4 40
KALEO INC 4 0 0 4 40
SCIENTURE 2 recent 2 0 0 0 40
JAZZ PHARMS 1 recent 4 0 0 2 40
CEPHALON 6 0 0 4 40
BIOMARIN PHARM 5 0 0 4 40
PHATHOM 1 recent 3 0 0 2 40
ALEXION PHARM 4 0 0 4 40
ACROTECH BIOPHARMA 1 recent 6 0 0 2 40
BIO-THERA SOLUTIONS LTD 2 recent 2 0 0 0 40
CATALYST PHARMS 1 recent 3 0 0 2 40
INSMED INC 1 recent 2 0 0 2 40
SERVIER 1 recent 2 0 0 2 40
FORMYCON AG 2 recent 2 0 0 0 40
SOFIE 3 2 2 2 34
LOTUS PHARM CO LTD 1 recent 6 0 0 1 30
UCSF RODIOPHARM 4 0 0 3 30
UNIV TX MD ANDERSON 4 0 0 3 30
CARDINAL HEALTH 414 5 0 0 3 30
MCPRF 4 0 0 3 30
ENDO PHARMS 7 0 0 3 30
US ARMY 5 0 0 3 30
ALMAJECT 1 recent 5 0 0 1 30
SAREPTA THERAPS INC 3 0 0 3 30
USWM 1 recent 4 0 0 1 30
EMD SERONO INC 8 0 0 3 30
AXSOME 1 recent 2 0 0 1 30
AGEPHA PHARMA FZ 1 recent 1 0 0 1 30
UNITED THERAP 5 0 0 3 30
AKARX INC 1 recent 2 0 0 1 30
PHARMACIA 6 0 0 3 30
ZEVRA DENMARK 1 recent 1 0 0 1 30
UROGEN PHARMA 1 recent 2 0 0 1 30
LEO PHARMA AS 1 recent 9 0 0 1 30
ASCENDIS PHARMA BONE 1 recent 1 0 0 1 30
DAY ONE BIOPHARMS 1 recent 1 0 0 1 30
CHIMERIX 1 recent 1 0 0 1 30
ARGENX BV 1 recent 2 0 0 1 30
BLUE EARTH 1 recent 2 0 0 1 30
ITALFARMACO SPA 1 recent 1 0 0 1 30
GENMAB US, INC. 1 recent 1 0 0 1 30
CHIRHOCLIN 3 0 0 3 30
TAIHO ONCOLOGY 3 0 0 3 30
PTC THERAP 1 recent 2 0 0 1 30
GUERBET 6 0 0 3 30
MDD US 1 recent 3 0 0 1 30
ARS PHARMS OPERATION 1 recent 1 0 0 1 30
STEALTH BIOTHERAPS 1 recent 1 0 0 1 30
NOVA LABS LTD 1 recent 2 0 0 1 30
SOLENO THERAP 1 recent 1 0 0 1 30
DIZAL JIANGSU 1 recent 1 0 0 1 30
LUMICELL 1 recent 1 0 0 1 30
NUVATION 1 recent 1 0 0 1 30
MERUS N.V. 1 recent 1 0 0 1 30
OTSUKA PHARM CO LTD 1 recent 2 0 0 1 30
MADRIGAL 1 recent 1 0 0 1 30
BRAEBURN 1 recent 1 0 0 1 30
CORMEDIX 1 recent 1 0 0 1 30
ISTX 1 recent 1 0 0 1 30
VERASTEM INC 1 recent 1 0 0 1 30
OMEROS CORP 1 recent 1 0 0 1 30

Why these companies? Emerging biotechs (1-10 approved drugs) with recent FDA approvals, priority reviews, or active late-stage pipelines represent potential acquisition targets or partnership opportunities.